Uppsala, July 29, 2012 -- Isconova AB (NASDAQ OMX First North: ISCO) will give a scientific presentation on Thursday 5th July, at 11:30 CET at Modern Vaccines Adjuvants & Delivery Systems – MVADS Conference (Copenhagen, July 4-6).
The development of novel generations of vaccines and therapies reinforces the need for development of new potent and safe adjuvants and delivery systems. Linda Stertman, PhD and R&D Director at Isconova, will present on Isconova’s proprietary adjuvant technology Matrix-M™ in preclinical studies and clinical trials. For more information about the conference program, please visit www.meetingsmanagement.co.uk.
About Isconova
Isconova AB is a leading international vaccine adjuvant company. Isconova has vast knowledge of vaccine systems and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconovas nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2005. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include J&J/Crucell, Pfizer, Merck & Co., The Jenner Institute and Genocea. The Company is headquartered in Uppsala, Sweden.
Isconova is listed on NASDAQ OMX First North (ticker: ISCO)
www.isconova.com
Contact:
Andrea Gottfridson
(+46) 18 16 17 13
abisco@isconova.com
